海昇药业
(870656)
| 流通市值：4.47亿 | | | 总市值：17.86亿 |
| 流通股本：2000.01万 | | | 总股本：8000.00万 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 186,341,856.34 | 314,755,697.46 | 454,706,743.51 | 101,382,799.16 |
| 应收票据及应收账款 | 20,631,299.26 | 17,009,978.65 | 37,187,461.62 | 36,130,183.7 |
| 其中：应收票据 | - | 338,059.81 | 1,535,089.67 | 4,187,750.5 |
| 应收账款 | 20,631,299.26 | 16,671,918.84 | 35,652,371.95 | 31,942,433.2 |
| 应收款项融资 | 13,134,020.7 | 4,119,262.93 | 2,207,650.78 | 5,479,751.78 |
| 预付款项 | 2,225,540.75 | 1,247,380.69 | 1,511,716.89 | 5,647,554 |
| 其他应收款合计 | 303,007.73 | 282,519.94 | 447,136.36 | 269,488.91 |
| 存货 | 27,051,865.27 | 33,954,257.79 | 29,701,122.56 | 28,592,659.82 |
| 其他流动资产 | 2,568,375.98 | 3,727,780.23 | 3,647,875.45 | 732,105.9 |
| 流动资产平衡项目 | 0 | 0 | 0 | -0.01 |
| 流动资产合计 | 508,255,966.03 | 505,096,877.69 | 529,409,707.17 | 178,234,543.26 |
| 非流动资产: | | | | |
| 固定资产 | 70,900,342.13 | 72,076,863.93 | 54,024,947.85 | 56,304,746.58 |
| 在建工程 | 56,713,845.91 | 44,569,219.66 | 54,098,648.76 | 37,472,611.67 |
| 无形资产 | 23,541,653.04 | 23,635,204.18 | 22,922,078.92 | 23,123,670.64 |
| 开发支出 | 886,158.14 | 102,720.78 | - | - |
| 长期待摊费用 | 519,247.45 | 416,570.97 | 410,416.68 | 358,490.57 |
| 递延所得税资产 | 207,305.58 | 175,561.89 | 325,080.45 | 300,393.37 |
| 其他非流动资产 | 12,905,957.39 | 16,528,525.29 | 15,655,514.29 | 11,580,811.14 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 165,674,509.64 | 157,504,666.7 | 147,436,686.95 | 129,140,723.97 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 673,930,475.67 | 662,601,544.39 | 676,846,394.12 | 307,375,267.23 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 13,659,886.81 | 13,380,868.94 | 11,329,136.97 | 12,926,459.73 |
| 其中：应付票据 | 3,855,372.23 | 5,963,780.44 | 4,002,321.47 | 9,405,439.41 |
| 应付账款 | 9,804,514.58 | 7,417,088.5 | 7,326,815.5 | 3,521,020.32 |
| 合同负债 | 641,310.94 | 232,815.36 | 252,125.1 | 532,303.77 |
| 应付职工薪酬 | - | - | - | 16,008 |
| 应交税费 | 2,253,755.78 | 1,741,582.06 | 3,979,587.56 | 5,364,890.75 |
| 其他应付款合计 | 21,701,336.6 | 21,799,685.07 | 2,791,287.55 | 3,457,560.73 |
| 其他流动负债 | 102,174.09 | 63,027.06 | 101,796.51 | 23,507.22 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 38,358,464.22 | 37,217,978.49 | 18,453,933.69 | 22,320,730.2 |
| 非流动负债: | | | | |
| 递延收益 | 429,121.48 | 506,645.12 | 584,168.76 | 661,692.4 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 429,121.48 | 506,645.12 | 584,168.76 | 661,692.4 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 38,787,585.7 | 37,724,623.61 | 19,038,102.45 | 22,982,422.6 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 80,000,000 | 80,000,000 | 80,000,000 | 60,000,000 |
| 资本公积 | 344,418,713.16 | 344,033,071.34 | 343,647,429.5 | 6,998,030.11 |
| 盈余公积 | 36,351,912.06 | 36,351,912.06 | 36,351,912.06 | 36,351,912.06 |
| 未分配利润 | 174,372,264.75 | 164,491,937.38 | 197,808,950.11 | 181,042,902.46 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 635,142,889.97 | 624,876,920.78 | 657,808,291.67 | 284,392,844.63 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 635,142,889.97 | 624,876,920.78 | 657,808,291.67 | 284,392,844.63 |
| 负债和股东权益合计 | 673,930,475.67 | 662,601,544.39 | 676,846,394.12 | 307,375,267.23 |
| 公告日期 | 2024-10-29 | 2024-08-28 | 2024-04-26 | 2024-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |